Figures
Abstract
Background
The impact of pre-existing diabetes on the development of acute lung injury/acute respiratory distress syndrome (ALI/ARDS) in critically ill patients remains unclear. We performed a meta-analysis of cohort studies to evaluate the risk of ALI/ARDS in critically ill patients with and without pre-existing diabetes.
Materials and Methods
We searched PubMed and Embase from the inception to September 2013 for cohort studies assessing the effect of pre-existing diabetes on ALI/ARDS occurrence. Pooled odds ratio (OR) with 95% confidence interval (CI) was calculated using random- or fixed-effect models when appropriate.
Results
Seven cohort studies with a total of 12,794 participants and 2,937 cases of pre-existing diabetes, and 2,457 cases of ALI/ARDS were included in the meta-analysis. A fixed-effects model meta-analysis showed that pre-existing diabetes was associated with a reduced risk of ALI/ARDS (OR 0.66; 95% CI, 0.55–0.80; p<0.001), with low heterogeneity among the studies (I2 = 18.9%; p = 0.286). However, the asymmetric funnel plot and Egger's test (p = 0.007) suggested publication bias may exist.
Citation: Gu W-J, Wan Y-D, Tie H-T, Kan Q-C, Sun T-W (2014) Risk of Acute Lung Injury/Acute Respiratory Distress Syndrome in Critically Ill Adult Patients with Pre-Existing Diabetes: A Meta-Analysis. PLoS ONE 9(2): e90426. https://doi.org/10.1371/journal.pone.0090426
Editor: Xiao Su, Chinese Academy of Sciences, China
Received: October 29, 2013; Accepted: January 30, 2014; Published: February 27, 2014
Copyright: © 2014 Gu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Acute lung injury (ALI) is a syndrome characterized by hypoxemia, noncardiogenic pulmonary edema, low lung compliance and widespread capillary leakage. When accompanied by more severe hypoxemia (PaO2/FiO2<200 mmHg), it is called acute respiratory distress syndrome (ARDS) [1]. Development of ALI/ARDS has been associated with short and long term morbidity, prolonged hospitalization, and high health-care costs [1]. Given the clinical consequences attributable to ALI/ARDS, identifying risk factors for prevention of ALI/ARDS is of great importance and is a priority in intensive care unit (ICU).
Diabetes also is a global health priority. The prevalence of diabetes is expected to dramatically increase by the year 2025 [2]. The proportion of critically ill patients with diabetes is also growing as a result of the worldwide increase in diabetes. However, the association between diabetes and mortality among ICU patients is still debatable. In some studies, pre-existing diabetes has been a risk factor of acute kidney injury in critically ill patients [3], [4], and has been associated with an increased mortality of surgical ICU [5], but in some other studies, diabetes does not alter mortality in ICU patients [6], [7], [8].
The impact of pre-existing diabetes on the development of ALI/ARDS remains unclear in critically ill patients, especially those with one or more predisposing conditions such as sepsis/septic shock, pneumonia, trauma, and aspiration. To our knowledge, the quality and consistency of epidemiological evidence on the topic have not been systematically investigated, which is an important gap in our understanding of the effect of pre-existing diabetes on the development of ALI/ARDS. With recently accumulating evidence, therefore, we performed a meta-analysis of cohort studies to evaluate the risk of ALI/ARDS in critically ill patients with and without pre-existing diabetes.
Materials and Methods
Search strategy
We performed this meta-analysis in accordance with the Meta-analysis of Observational Studies in Epidemiology(MOOSE) statement [9]. PubMed and Embase databases from inception to September 2013 were searched to identify relevant studies, without language restrictions. Search terms included “diabetes”, “DM”, “acute respiratory distress syndrome”, “acute lung injury”, “ARDS”, “ALI”, and “acute respiratory failure”. In addition, we reviewed the reference lists of retrieved papers and recent reviews to identify other potentially eligible studies that we had not captured with our primary search.
Study selection
The following inclusive selection criteria were applied: (a) study design: cohort study; (b) study population: critically ill adult patients, it meaned ICU or emergency patients with ALI/ARDS predisposing risk factors, including sepsis, septic shock, pancreatitis, pneumonia, aspiration, trauma, or high-risk surgery; (c) comparison intervention: with and without pre-existing diabetes; and (d) outcome measure: the development of ALI/ARDS. In the case of duplicate data publication (several studies with overlapping samples), we only included the most informative article or complete study to avoid duplication of information.
Data extraction and quality assessment
A standardized data collection form was used to extract the following information from each included article: first author, publication year, sample size, number of diabetes cases, number of ALI/ARDS cases, population characteristics, type of study design, definition of ALI/ARDS, and odds ratios (ORs) with the corresponding 95% confidence intervals (CIs) on multivariable analysis. The supplementary files were also examined for data extraction. Where necessary, we contacted authors of included studies for additional information.
We assessed the methodological quality of each study on 8 items used in the Newcastle-Ottawa Scales (NOS) [10]. We assigned risk of bias categories based on the number of Newcastle–Ottawa Scales (NOS) items judged inadequate in each study, as follows: low risk of bias (0–1 inadequate item); medium risk of bias (2–3 inadequate items); high risk of bias (over 3 inadequate items); very high risk of bias (no description of methods).
Two investigators (WJ Gu and YD Wan) independently conducted the study selection, data extraction and quality assessment, a third investigator (TW Sun) was consulted to resolve any discrepancies.
Statistical analysis
OR was used as a common measure of the association between pre-existing diabetes and the development of ALI/ARDS across studies. Heterogeneity was tested using the Cochran Q statistic (p<0.1) and quantified with the I2 statistic, which describes the variation of effect size that is attributable to heterogeneity across studies [11]–[13]. An I2 value greater than 50% indicates significant heterogeneity. The value of the I2 statistic was used to select the appropriate pooling method: fixed-effects models were used for I2< 50% and random-effects models for I2≥50% [11]–[13]. To explore the possible source of heterogeneity and to examine the influence of various clinical factors on the overall risk estimate, we further carried out prior subgroup analyses according to study design (prospective vs. retrospective), predisposing conditions (sepsis/septic shock vs. >1 predisposing conditions), study center (single-center vs. multicenter), and sample size(≤1000 vs. >1000). We also investigated the influence of a single study on the overall pooled estimate by omitting one study in each turn. Potential publication bias was detected by Begg's funnel plots and Egger's regression test [14], [15]. A p value <0.05 was judged as statistically significant, except where otherwise specified. All statistical analyses were performed using STATA, version 11.0 (Stata Corp).
Results
Study selection and study characteristics
The initial search yielded 826 relevant publications, of which 819 were excluded for duplicate studies and various reasons (reviews, animal studies, or not relevant to our analysis) on the basis of the title/abstract and full text (see the detail in Figure 1). The remaining seven cohort studies were included in the final analysis [15]–[21].
The main characteristics of the seven included cohort studies are shown in Table 1. These studies were published between 2000 and 2013. In total, 12,794 participants, 2,937 cases of pre-existing diabetes, and 2,457 cases of ALI/ARDS were enrolled. All the included studies use the same definition of ALI/ARDS (American-European Consensus Conference definition) [22]. The average NOS score of the studies included was 6.7 (range from 6 to 7). An additional file shows this in more detail [see File S1].
Pre-existing diabetes and the risk of ALI/ARDS
Figure 2 shows the pooled results from the fixed-effects model combing the ORs for ALI/ARDS. Overall, 12,794 patients were included in this analysis (2,937 cases of pre-existing diabetes and 2,457 cases of ALI/ARDS). Pre-existing diabetes was associated with a decreased risk of ALI/ARDS in critically ill adult patients (OR 0.66; 95% CI, 0.55–0.80; p<0.001), with low heterogeneity among the studies (I2 = 18.9%; p = 0.286). Further exclusion of any single study did not materially alter the overall combined OR, with a range of from 0.55 (95% CI, 0.41–0.74) to 0.68 (95% CI, 0.56–0.83). Table 2 shows the results of subgroup analyses for ALI/ARDS. The finding of decreased risk of ALI/ARDS in critically ill adult patients was consistently found in most subgroup analyses.
Publication bias
Egger's test (p = 0.007) suggested that publication bias may exist. Also, there was asymmetry in the lower segments of the funnel plot in which small negative trials were missing (Figure 3), potentially leading to overstatement of the treatment effect. But the low power with only seven studies limited the interpretability of the finding.
Discussion
Main findings
To the best of our knowledge, this is the first meta-analysis to explore the association between pre-existing diabetes and the risk of ALI/ARDS in critically ill adult patients. Our meta-analysis of seven cohort studies suggests that pre-existing diabetes was associated with a decreased risk of ALI/ARDS in critically ill adult patients. In addition, the association was consistently found in most subgroup analyses.
Possible mechanism
Although pre-existing diabetes may decrease the risk of ALI/ARDS, the mechanism remains unclear. Since inflammation plays an important role in the onset and progression of ALI/ARDS [23], several studies have suggested that the protective effect of diabetes for ALI/ARDS may result from the reduced inflammatory response [24], [25]. Filgueiras and colleagues [24] reported that in non-diabetic rats with ALI/ARDS secondarily to sepsis, the lung presented edema, leukocyte infiltration, and increased COX2 expression; however, these inflammatory events were less intense in diabetic rats. Similarly, in the diabetic mice with infection, the inflammatory response is lower compared with non-diabetic mice [25]. Decreased inflammatory response may be associated with attenuation of cytokine release and reduction of neutrophil migration [25]. The involved cytokines included PPAR-γ [26], nuclear factor-κB [27], insulin-like growth factor-1 [27], [28], leptin, and development of advanced glycation end products [29], [30]. For the neutrophil migration, α1-acid glycoprotein is important in the failure of this process after sepsis [31], but the mechanism is not completely understood.
On another note, diabetes therapy modifies some effects that diabetes may have on ALI/ARDS. Insulin is usually the only diabetic treatment that is continued during critical illness. Independent of glycemic control, insulin has been shown to be immunomodulatory Independent of glycemic control [32]. In clinical studies, intensive insulin therapy may decrease mortality for critically ill patients [33], However, it is difficult to know whether insulin may be detrimental or beneficial in ALI/ARDS. According to our study, diabetes is protective in ALI/ARDS, then reversal of the anti-inflammatory effects of diabetes by insulin may negate the beneficial effect of diabetes on ALI/ARDS. Alternatively, if insulin reverses the chronic immunosuppressive effects of diabetes and restores the balance in inflammatory response, then insulin may be potentially beneficial [34]. More studies are needed to determine whether insulin is detrimental or beneficial in ALI/ARDS. Other drug commonly used was metformin, which was recently shown to reduce oxidative injury [35]. But the possible mechanism of diabetes therapy on ALI/ARDS still remains unclear.
Clinical implications
Our findings are of clinical significance to some extent. The most consistent evidence was the decreased risk of ALI/ARDS in critically ill adult patients with pre-existing diabetes. Currently, physicians caring for critically ill patients can not accurately determine which patient will develop ALI/ARDS, since no biological markers have been found to predict it precisely so far [36], [37]; however, physicians could roughly predict who was more likely to worsen to ALI/ARDS according to the risk factors in critically ill patients. The following risk factors have been found: alcohol abuse [38], hypoalbuminemia [15], [39], transfusions [15], tachypnea [16], high tidal volumes [40], and obesity [41]. Besides, diabetes, as another risk factor of ALI/ARDS has been paid more attention [14]–[20]. However, to our knowledge, whether pre-existing diabetes will protect patients from converting to ALI/ARDS or facilitate the development of ALI/ARDS remains still unknown. Our meta-analysis suggested pre-existing diabetes was associated with a decreased risk of ALI/ARDS in critically ill adult patients. The findings, for the clinicians, may contribute to the sorting and management of critically ill patients with diabetes, as a protective factor for ALI/ARDS. As a primary prevention strategy, excluding risk factors is equally important to identifying those. Diabetes may be excluded from the high risk factors of ALI/ARDS.
Strengths and limitations
Strengths of this meta-analysis included its exhaustive search without language restrictions and validated systematic review methods following the MOOSE guidelines. Also, all included studies were cohort studies and high-quality, with an average NOS score of 6.7 allowing for the impossibility of randomized controlled trial. High-quality cohort studies may minimize the likelihood of recall bias, which is of particular concern in other epidemiological study designs.
Several limitations of this meta-analysis merit consideration. First, the characteristics of populations, the type of diabetes (type 1 or type 2), the definition of diabetes, severity of the illness, and the adjusted confounding factor were not strictly described in some trials. These factors may result in heterogeneity and have a potential impact on our results. Second, the critically ill patients was really a broad population, in our study, most studies described it as ICU patients with one or more ALI/ARDS predisposing risk factors, including sepsis, septic shock, pancreatitis, pneumonia, aspiration, trauma, or high-risk surgery, etc. So whether the conclusion was suitable for the unselected ICU population remain questionable. Third, both the asymmetric funnel plot and Egger's test suggested publication bias may exist. Small negative trials were missing, potentially resulting in overstatement of the treatment effect. Furthermore, we are unable to assess the impact of pre-existing diabetes on other clinically meaningful end points, such as mortality attributed to ALI/ARDS, because of sparse and inconsistent reporting across studies.
Conclusions
In summary, this meta-analysis of seven cohort studies suggests that pre-existing diabetes decreased the risk of ALI/ARDS in critically ill adult patients; however, the result should be interpreted with caution because of the potential bias and confounding in the included studies.
Supporting Information
File S1.
Methodological quality assessment (risk of bias) of included studies by Newcastle-Ottawa Scales.
https://doi.org/10.1371/journal.pone.0090426.s002
(DOC)
Author Contributions
Conceived and designed the experiments: WJG YDW HTT QCK TWS. Performed the experiments: WJG YDW HTT. Analyzed the data: WJG YDW HTT QCK TWS. Contributed reagents/materials/analysis tools: WJG YDW HTT QCK TWS. Wrote the paper: WJG YDW.
References
- 1. Rubenfeld GD, Herridge MS (2007) Epidemiology and outcomes of acute lung injury. Chest 131: 554–562.
- 2. King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21: 1414–1431.
- 3. Cartin-Ceba R, Kashiouris M, Plataki M, Kor DJ, Gajic O, et al. (2012) Risk factors for development of acute kidney injury in critically ill patients: a systematic review and meta-analysis of observational studies. Crit Care Res Pract 2012: 691013.
- 4. Christiansen CF, Johansen MB, Christensen S, O'Brien JM, Tonnesen E, et al. (2013) Type 2 diabetes and 1-year mortality in intensive care unit patients. Eur J Clin Invest 43: 238–247.
- 5. Siegelaar SE, Hickmann M, Hoekstra JB, Holleman F, DeVries JH (2011) The effect of diabetes on mortality in critically ill patients: a systematic review and meta-analysis. Crit Care 15: R205.
- 6. Stegenga ME, Vincent JL, Vail GM, Xie J, Haney DJ, et al. (2010) Diabetes does not alter mortality or hemostatic and inflammatory responses in patients with severe sepsis. Crit Care Med 38: 539–545.
- 7. Graham BB, Keniston A, Gajic O, Trillo AC, Medvedev S, et al. (2010) Diabetes mellitus does not adversely affect outcomes from a critical illness. Crit Care Med 38: 16–24.
- 8. Vincent JL, Preiser JC, Sprung CL, Moreno R, Sakr Y (2010) Insulin-treated diabetes is not associated with increased mortality in critically ill patients. Crit Care 14: R12.
- 9. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008–2012.
- 10.
Wells GA SB, O'Connell D, Peterson J, Welch V, Losos M, et al. (2013) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. Available: www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
- 11. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Controlled clinical trials 7: 177–188.
- 12. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557–560.
- 13. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088–1101.
- 14. Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.
- 15. Moss M, Guidot DM, Steinberg KP, Duhon GF, Treece P, et al. (2000) Diabetic patients have a decreased incidence of acute respiratory distress syndrome. Crit Care Med 28: 2187–2192.
- 16. Gong MN, Thompson BT, Williams P, Pothier L, Boyce PD, et al. (2005) Clinical predictors of and mortality in acute respiratory distress syndrome: potential role of red cell transfusion. Crit Care Med 33: 1191–1198.
- 17. Iscimen R, Cartin-Ceba R, Yilmaz M, Khan H, Hubmayr RD, et al. (2008) Risk factors for the development of acute lung injury in patients with septic shock: an observational cohort study. Crit Care Med 36: 1518–1522.
- 18. Gajic O, Dabbagh O, Park PK, Adesanya A, Chang SY, et al. Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators (USCIITG-LIPS) (2011) Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score in a multicenter cohort study. Am J Respir Crit Care Med 183: 462–470.
- 19. Trillo-Alvarez C, Cartin-Ceba R, Kor DJ, Kojicic M, Kashyap R, et al. (2011) Acute lung injury prediction score: derivation and validation in a population-based sample. Eur Respir J 37: 604–609.
- 20. Koh GC, Vlaar AP, Hofstra JJ, de Jong HK, van Nierop S, et al. (2012) In the critically ill patient, diabetes predicts mortality independent of statin therapy but is not associated with acute lung injury: a cohort study. Crit Care Med 40: 1835–1843.
- 21. Yu S, Christiani DC, Thompson BT, Bajwa EK, Gong MN (2013) Role of diabetes in the development of acute respiratory distress syndrome. Crit Care Med 41: 2720–2732.
- 22. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, et al. (1994) The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149: 818–824.
- 23. Kollef MH, Schuster DP (1995) The acute respiratory distress syndrome. N Engl J Med 332: 27–37.
- 24. Filgueiras LJ, Martins JO, Serezani CH, Capelozzi VL, Montes MB, et al. (2012) Sepsis-induced acute lung injury (ALI) is milder in diabetic rats and correlates with impaired NFkB activation. PLoS One 7: e44987.
- 25. Spiller F, Carlos D, Souto FO, de Freitas A, Soares FS, et al. (2012) α1-Acid glycoprotein decreases neutrophil migration and increases susceptibility to sepsis in diabetic mice. Diabetes 61: 1584–1591.
- 26. Genovese T, Mazzon E, Di Paola R, Muia C, Crisafulli C, et al. (2005) ROLE OF ENDOGENOUS AND EXOGENOUS LIGANDS FOR THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR alpha IN THE DEVELOPMENT OF BLEOMYCIN-INDUCED LUNG INJURY. Shock 24: 547–555.
- 27. Krein PM, Sabatini PJ, Tinmouth W, Green FH, Winston BW (2003) Localization of insulin-like growth factor-I in lung tissues of patients with fibroproliferative acute respiratory distress syndrome. Am J Respir Crit Care Med 167: 83–90.
- 28. Schnapp LM, Donohoe S, Chen J, Sunde DA, Kelly PM, et al. (2006) Mining the acute respiratory distress syndrome proteome: identification of the insulin-like growth factor (IGF)/IGF-binding protein-3 pathway in acute lung injury. Am J Pathol 169: 86–95.
- 29. Zhang H, Tasaka S, Shiraishi Y, Fukunaga K, Yamada W, et al. (2008) Role of soluble receptor for advanced glycation end products on endotoxin-induced lung injury. Am J Respir Crit Care Med 178: 356–362.
- 30. Calfee CS, Ware LB, Eisner MD, Parsons PE, Thompson BT, et al. (2008) Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax 63: 1083–1089.
- 31. Mestriner FL, Spiller F, Laure HJ, Souto FO, Tavares-Murta BM, et al. (2007) Acute-phase protein alpha-1-acid glycoprotein mediates neutrophil migration failure in sepsis by a nitric oxide-dependent mechanism. Proc Natl Acad Sci U S A 104: 19595–19600.
- 32. Hansen TK, Thiel S, Wouters PJ, Christiansen JS, Van den Berghe G (2003) Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 88: 1082–1088.
- 33. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, et al. (2006) Intensive insulin therapy in the medical ICU. N Engl J Med 354: 449–461.
- 34. Honiden S, Gong MN (2009) Diabetes, insulin, and development of acute lung injury. Crit Care Med 37: 2455–2464.
- 35. Zmijewski JW, Lorne E, Zhao X, Tsuruta Y, Sha Y, et al. (2008) Mitochondrial respiratory complex I regulates neutrophil activation and severity of lung injury. Am J Respir Crit Care Med 178: 168–179.
- 36. Janz DR, Ware LB: Biomarkers of ALI/ARDS (2013) Pathogenesis, Discovery, and Relevance to Clinical Trials. Semin Respir Crit Care Med 34: 537–548.
- 37. Cepkova M, Brady S, Sapru A, Matthay MA, Church G (2006) Biological markers of lung injury before and after the institution of positive pressure ventilation in patients with acute lung injury. Crit Care 10: R126.
- 38. Moss M, Bucher B, Moore FA, Moore EE, Parsons PE (1996) The role of chronic alcohol abuse in the development of acute respiratory distress syndrome in adults. JAMA 275: 50–54.
- 39. Mangialardi RJ, Martin GS, Bernard GR, Wheeler AP, Christman BW, et al. (2000) Hypoproteinemia predicts acute respiratory distress syndrome development, weight gain, and death in patients with sepsis. Ibuprofen in Sepsis Study Group. Crit Care Med 28: 3137–3145.
- 40. Gajic O, Frutos-Vivar F, Esteban A, Hubmayr RD, Anzueto A (2005) Ventilator settings as a risk factor for acute respiratory distress syndrome in mechanically ventilated patients. Intensive Care Med 31: 922–926.
- 41. Gong MN, Bajwa EK, Thompson BT, Christiani DC (2010) Body mass index is associated with the development of acute respiratory distress syndrome. Thorax 65: 44–50.